Group 1 - The core viewpoint of the articles highlights the promising clinical results of Rovadicitinib for treating acute graft-versus-host disease (aGVHD), showing an overall response rate (ORR) of 84.6% over 28 days and a 12-month overall survival rate of 92.3% [1][2] - Rovadicitinib is the first dual-pathway JAK/ROCK inhibitor globally, representing a significant breakthrough in the treatment of graft-versus-host disease (GVHD) [2] - The drug targets multiple pathways involved in aGVHD, potentially offering better treatment options for patients who are steroid-resistant [1] Group 2 - Clinical data indicates a median response time of only 4 days and an 80% intestinal response rate, demonstrating rapid efficacy and sustained relief [1] - Within 56 days, 38.5% of patients were able to completely discontinue steroid use, significantly reducing the long-term side effects associated with immunosuppression [1] - The company has initiated a Phase III clinical trial for Rovadicitinib in treating chronic graft-versus-host disease (cGVHD), currently in the subject enrollment phase [2]